Printer Friendly

MEDAMICUS ANNOUNCES LETTER OF INTENT WITH EMPI, INCORPORATED

 MINNEAPOLIS, May 21 /PRNewswire/ -- MedAmicus, Inc. (NASDAQ: MEDM) announced today that it has signed a letter of intent with Empi, Incorporated (NASDAQ: EMPI) to enter into an exclusive distribution agreement whereby Empi would market MedAmicus' LUMAX Dual Channel Fiber Optic Cystometry System designed to conduct diagnostic screening for urinary incontinence. If finalized, MedAmicus will grant Empi worldwide exclusive distribution rights to the product, subject to the purchase by Empi of certain minimum quantities of pressure monitoring catheters. The signing of this letter of intent was first reported by Empi at their annual meeting on May 19.
 In addition, the letter of intent calls for Empi to provide MedAmicus with $1,500,000 of debt financing in three installments: $500,000 upon signing of the distribution agreement, which is expected to occur within the next several months, and based on results of test marketing, two additional debt placements of $500,000 each. The three debt financings would be convertible into MedAmicus common stock at conversion prices of $4.25, $5.25 and $6 per share, respectively.
 MedAmicus' president and CEO, Richard L. Little, stated that the relationship is a very positive step for the company and said that "... Empi's 100 plus direct sales force will provide a much faster entry into the rapidly developing incontinence testing market than we could achieve through the establishment of our own distribution network."
 In addition to the LUMAX Dual Channel Cystometry System which is the subject of the company's letter of intent with Empi, MedAmicus has also developed and intends to market a three channel "interface" monitor which would allow existing hospital and clinic based urodynamic testing systems to use the company's fiber optic catheter.
 MedAmicus, Inc. is a Plymouth, Minn.-based medical products company engaged in the design, development, manufacture and marketing of disposable vascular access and pressure monitoring devices.
 -0- 5/21/93
 /CONTACT: James Hartman of MedAmicus, 612-559-2613/
 (MEDM)


CO: MedAmicus, Inc. ST: Minnesota IN: MTC SU: JVN

AL -- MN009 -- 1183 05/21/93 11:54 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1993
Words:335
Previous Article:NATIONAL COMPUTER SYSTEMS, INC. ANNOUNCES QUARTERLY CASH DIVIDEND
Next Article:NORTH EAST INSURANCE COMPANY REPORTS RESULTS
Topics:


Related Articles
MEDAMICUS ANNOUNCES SIGNING OF LETTER OF INTENT
MEDAMICUS, INC. AND MEDTRONIC, INC.
MEDAMICUS ANNOUNCES SIGNING OF INVESTMENT AGREEMENT WITH EMPI
EMPI FINALIZES INVESTMENT AND TEST MARKETING AGREEMENT FOR TWO INCONTINENCE PRODUCTS DEVELOPED BY MEDAMICUS, INC.
MEDAMICUS/EMPI AGREEMENT DEADLINE EXPIRES
EMPI, MEDAMICUS UNABLE TO FINALIZE DISTRIBUTION AGREEMENT
MEDAMICUS, INC. ANNOUNCES GERMAN DISTRIBUTION AGREEMENT
EMPI ANNOUNCES AGREEMENT WITH REHAB MED EQUIP, INC.
MEDAMICUS ANNOUNCES INDEPENDENT CONTRACTOR AGREEMENTS
EMPI, INC. OBTAINS ADDITIONAL MARKETING RIGHTS; EXPANDS REHABILITATION PRODUCT LINES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters